Plasmodium Immunotherapy for Advanced Malignant Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors — Stella

Recruiting

Back to Advanced Malignant Solid Tumor trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Yunnan Kungang Hospital, Kunming, Yunnan

Key details

Phase

Early testing / Safety & dosing

Sponsor

CAS Lamvac Biotech Co., Ltd.

Enrollment target

~60 participants

Started

October 2019

Primary completion

April 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated February 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov